Hepion Pharmaceuticals CFO John Brancaccio resigns effective Monday

Hepion Pharmaceuticals, Inc. (NASDAQ:OTC:HEPA) announced that John Brancaccio, its Chief Financial Officer and a member of the board of directors, has resigned from both positions. The resignation is effective Monday. According to a statement in the company’s SEC filing, Brancaccio’s departure is for personal reasons. The transition comes at a critical time for the micro-cap company, which currently has a market capitalization of just $770,000 and maintains a weak financial health score according to InvestingPro analysis.

The filing, submitted Monday, states that Brancaccio notified the company of his decision on June 25, 2025. Hepion Pharmaceuticals is incorporated in Delaware and is based in Morristown, New Jersey. The company maintains a strong liquidity position with a current ratio of 6.75, indicating substantial cash reserves relative to short-term obligations.

Following Brancaccio’s resignation, Kaouthar Lbiati has been named Interim Chief Financial Officer, as indicated by her signature on the filing.

This information is based on a statement from the company’s press release included in its recent SEC filing.

In other recent news, Hepion Pharmaceuticals is facing significant changes as it prepares for delisting from the Nasdaq Stock Market due to noncompliance with listing standards, specifically failing to meet the minimum bid price requirement. Following this development, the company anticipates trading its common stock on the OTC Markets Group. Amid these challenges, Hepion has entered a licensing agreement with New Day Diagnostics LLC, expanding its focus to include diagnostic tests for diseases such as celiac disease and respiratory illnesses. These tests, which have received CE marks, are targeted for the European market, addressing a combined market projected to exceed $15 billion. Additionally, Hepion’s recent annual meeting included the election of four directors and the ratification of its independent auditors, although a proposal for a reverse stock split was not approved. The company’s shift from drug development to diagnostics follows the winding down of its ASCEND-NASH clinical trial for Rencofilstat, its primary asset. Hepion’s strategic pivot aims to leverage new opportunities and generate near-term revenue in the European Union. Investors are advised to consider the company’s recent SEC filings for detailed risk factors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.